A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza) versus fludarabine and cytarabine (Fluga Scheme) in elderly patients with newly diagnosed acute myeloid leukemia.

Trial Profile

A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza) versus fludarabine and cytarabine (Fluga Scheme) in elderly patients with newly diagnosed acute myeloid leukemia.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 May 2018

At a glance

  • Drugs Azacitidine (Primary) ; Cytarabine; Cytarabine; Fludarabine; Fludarabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms FLUGAZA
  • Most Recent Events

    • 22 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 28 Nov 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
    • 28 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top